Anna Posadzy-Małaczyńska

Anna Posadzy-Małaczyńska

Auto-generated profile, based on publicly available information

Anna Posadzy-Małaczyńska

Department of Family Medicine, Poznan University of Medical Sciences, Poznan, Poland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
KMKatarzyna Małaczyńska-Rajpold
Katarzyna Małaczyńska-Rajpold
KBKrzysztof Błaszyk
Krzysztof Błaszyk
AKAnna Kociemba
Anna Kociemba
MPMałgorzta Pyda
Małgorzta Pyda
APAnna Posadzy‐Malaczynska
Anna Posadzy‐Malaczynska
Stefan GrajekStefan Grajek
Stefan Grajek

13 December 2013 in Polish Heart Journal
Verified
Journal Article
Open access
APAnna Posadzy-Małaczyńska
Anna Posadzy-Małaczyńska
LWLucyna Woźnicka-Leśkiewicz
Lucyna Woźnicka-Leśkiewicz
RJRobert Juszkat
Robert Juszkat
MFMaciej Frankiewicz
Maciej Frankiewicz
AKAnna Kociemba
Anna Kociemba

30 October 2018 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
LWLucyna Woznicka-Leskiewicz
Lucyna Woznicka-Leskiewicz
APAnna Posadzy-Małaczyńska
Anna Posadzy-Małaczyńska
JMJustyna Marcinkowska
Justyna Marcinkowska
Background: The aims of the study were to assess subclinical organ damage in men and women with hypertension and its subsequent effect on cardiovascular risk, and use of new statistical methods for more precise estimation of cardiovascular risk using vascular cardiovascular risk factors: ankle–brachial index (ABI), intima–media thickness (IMT) and pulse wave velocity (PWV). Methods: We studied 200 patients: 100 hypertensive and 100 normotensive. The parameters we evaluated included: patient age, ABI, IMT, PWV, serum uric acid and serum C-reactive protein (CRP). In addition, the cardiovascular risk according to the SCORE and Framingham scales was assessed. Results: In the hypertensive group, there were significant correlations between ABI and the Framingham scale in both sexes. In hypertensive women, there were also significant correlations between IMT and the SCORE scale risk, and IMT and the Framingham scale risk. In normotensive women, there were significant correlations between ABI and the SCORE scale risk, and between ABI and the Framingham scale risk. In normotensive men, there were significant correlations between PWV and the SCORE scale risk, and between PWV and the Framingham scale risk. Lastly, in the group of normotensive men, there were significant correlations between IMT and the SCORE scale risk, and IMT and the Framingham scale risk. The possibility of correctly classifying a patient into the high-risk category by a logistic regression model using synchronous ABI, IMT and PWV was high – 74% for the risk according to the SCORE scale (66% in men, 88% in women), and 98% for the Framingham scale. Conclusions: The addition of recognized subclinical target organ damage tests to the estimation of cardiovascular risk can significantly strengthen the prevention of cardiovascular disease. Cardiovascular risk estimation follow-up with ABI, PWV and IMT increased the probability of correctly classifying people, especially women, into an at least high-risk category according to the SCORE scale, which has valuable therapeutic implications.